These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27089726)

  • 1. [TARTRAT-RESISTANT ACID PHOSPHATASE AS BONE'S RESORBTION MARKER IN PATIENTS WITH BONE METASTASES].
    Dedkov AG; Boychuk SI; Stakhovsky EA; Kukushkina MN; Kovalchuk PA
    Lik Sprava; 2015; (5-6):104-9. PubMed ID: 27089726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
    Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
    Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.
    Capeller B; Caffier H; Sütterlin MW; Dietl J
    Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PREVENTION OF THE BONES METASTASES OCCURRENCE IN THE PATIENTS WITH RENAL-CELL CANCER].
    Boychuk SI; Dedkov AG; Yugrinova LG
    Klin Khir; 2015 Dec; (12):44-7. PubMed ID: 27025032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
    Halleen JM
    Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases.
    Tauchert S; di Liberto A; Cordes T; Thill M; Salehin D; Friedrich M
    Clin Exp Obstet Gynecol; 2009; 36(4):219-25. PubMed ID: 20101852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
    Chao TY; Wu YY; Janckila AJ
    Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
    Wu ZQ; Zhang Y; Xie E; Song WJ; Yang RX; Yan CJ; Zhang BF; Xu HG
    PLoS One; 2016; 11(1):e0147554. PubMed ID: 26800211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker].
    Nowak Z; Konieczna M; Saracyn M; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):351-4. PubMed ID: 18634372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
    Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
    Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
    Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
    Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
    Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
    Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
    Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tartrate-resistant acid phosphatase as a serum marker of bone resorption.
    Halleen JM; Ranta R
    Am Clin Lab; 2001 Jul; 20(6):29-30. PubMed ID: 11480390
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.